Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-28T19:21:10.225Z Has data issue: false hasContentIssue false
  • English
  • Français

Atrioventricular septal defect with separate right and left atrioventricular valvar orifices in a patient with foetal hydantoin syndrome

Published online by Cambridge University Press:  19 August 2008

Victor Grech  and
Cecil Vella
Victor Grech*
Affiliation:
Paediatric Department, St Luke's Hospital, Guardamangia, Malta
Cecil Vella
Affiliation:
Paediatric Department, St Luke's Hospital, Guardamangia, Malta
*
Victor Grech, MRCR Paediatric Department, St Luke's Hospital, Guardamangia, Malta. Tel: 241251 ext. 1471; Fax: 240176
Get access Rights & Permissions [Opens in a new window]

Abstract

The teratogenic properties of phenytoin, including cardiac malformations, have been previously documented. We report one patient with foetal hydantoin syndrome and atrioventricular septal defect with common atrioventricular junction but separate right and left atrioventricular valves, an association that has not been described, to the best of our knowledge.

Keywords

Heart defects-congenitalendocardial cushion defectsanticonvulsants-adverse effectsfoetal diseases-chemically induced
Type
Brief Reports
Information
Cardiology in the Young , Volume 9 , Issue 1 , January 1999 , pp. 73 - 74
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Gilman, AG, Rall, TW, Nies, AS, Taylor, PThe Pharmacologic Basis of Therapeutics. McGraw-Hill, New York, 1990.Google Scholar
2.Meadow, SR. Anticonvulsant drugs and congenital abnormalities. Lancet 1968; ii: 1296.CrossRefGoogle Scholar
3.Fedrick, J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. Br Med J 1973; 2: 442–448.CrossRefGoogle ScholarPubMed
4.Monson, RR, Rosenbery, L, Hartz, SC, Saphiro, S, Heinonen, OP, Slone, D. Diphenylhydantoin and selected congenital malformations. N Engl J Med 1973; 289: 1049–1052.CrossRefGoogle ScholarPubMed
5.Speidel, BD, Meadow, SR. Maternal epilepsy and abnormalities of the foetus and newborn. Lancet 1972; ii: 839–843.CrossRefGoogle Scholar
6.American Academy of Pediatrics Committee on Drugs. Anticonvulsants and pregnancy. Pediatrics 1979; 63: 331–333.CrossRefGoogle Scholar
7.Hanson, JW, Myrianthopoulos, NC, Sedgwick Harvey, MA, Smith, DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the foetal hydantoin syndrome. J Pediatr 1976; 89: 662–668.CrossRefGoogle Scholar
8.Buehler, BA, Delimont, D, van Waes, M, Finnell, RH. Prenatal prediction of risk of the foetal hydantoin syndrome. N Engl J Med 1990; 322: 1567–1572.CrossRefGoogle Scholar
9.Fedrick, J. Epilepsy and pregnancy. Br Med J 1973; 2: 442–448.CrossRefGoogle ScholarPubMed
10.Bartoshesky, LE, Bhan, I, Nagpaul, K, Pashayan, H. Severe cardiac and ophthalmologic malformations in an infant exposed to diphenylhydantoin in Men. Pediatrics 1982; 69: 202–203.CrossRefGoogle Scholar